Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta‐analysis
Guofeng Chen(302 Military Hospital of China), George Lau(Humanity & Health), Yudong Wang(Shanxi University), Jing Chen(Chinese Academy of Sciences), Cheng Wang(Gansu Provincial Maternal and Child Health Hospital), Dong Ji(Humanity & Health), Johan Karlberg(University of North Carolina at Chapel Hill), Vanessa Wu(Humanity & Health)
Cited by 160
Related Papers
Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B
|New England Journal of Medicine|2005|1.5k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
The neglected health of international migrant workers in the COVID-19 epidemic
|The Lancet Psychiatry|2020|402
Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.
|Journal of Clinical Oncology|2022|398
Hepatocellular Carcinoma (HCC)
|Journal of Clinical Gastroenterology|2010|322